These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 10541775

  • 1. Assessment of analgesia in human chronic pain. Randomized double-blind crossover study of once daily repro-dose morphine versus MST continus.
    Peat S, Sweet P, Miah Y, Barklamb M, Larsen U.
    Eur J Clin Pharmacol; 1999 Oct; 55(8):577-81. PubMed ID: 10541775
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, multi-site, crossover, placebo-controlled equivalence study of morning versus evening once-daily sustained-release morphine sulfate in people with pain from advanced cancer.
    Currow DC, Plummer JL, Cooney NJ, Gorman D, Glare PA.
    J Pain Symptom Manage; 2007 Jul; 34(1):17-23. PubMed ID: 17601560
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of twenty-four-hourly Kapanol compared to twelve-hourly MS Contin in the treatment of severe cancer pain.
    Gourlay GK, Cherry DA, Onley MM, Tordoff SG, Conn DA, Hood GM, Plummer JL.
    Pain; 1997 Feb; 69(3):295-302. PubMed ID: 9085304
    [Abstract] [Full Text] [Related]

  • 6. Patient-controlled analgesia for mucositis pain in children: a three-period crossover study comparing morphine and hydromorphone.
    Collins JJ, Geake J, Grier HE, Houck CS, Thaler HT, Weinstein HJ, Twum-Danso NY, Berde CB.
    J Pediatr; 1996 Nov; 129(5):722-8. PubMed ID: 8917240
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain.
    Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I.
    J Clin Oncol; 1998 Oct; 16(10):3222-9. PubMed ID: 9779695
    [Abstract] [Full Text] [Related]

  • 10. Efficacy, safety, and steady-state pharmacokinetics of once-a-day controlled-release morphine (MS Contin XL) in cancer pain.
    Hagen NA, Thirlwell M, Eisenhoffer J, Quigley P, Harsanyi Z, Darke A.
    J Pain Symptom Manage; 2005 Jan; 29(1):80-90. PubMed ID: 15652441
    [Abstract] [Full Text] [Related]

  • 11. Controlled-release morphine (MST Contin) in advanced cancer. The European experience.
    Hanks GW.
    Cancer; 1989 Jun 01; 63(11 Suppl):2378-82. PubMed ID: 2655869
    [Abstract] [Full Text] [Related]

  • 12. Steady-state pharmacokinetic comparison of a new, extended-release, once-daily morphine formulation, Avinza, and a twice-daily controlled-release morphine formulation in patients with chronic moderate-to-severe pain.
    Portenoy RK, Sciberras A, Eliot L, Loewen G, Butler J, Devane J.
    J Pain Symptom Manage; 2002 Apr 01; 23(4):292-300. PubMed ID: 11997198
    [Abstract] [Full Text] [Related]

  • 13. A randomized, double-blind, placebo-controlled, cross-over pilot study to assess the effects of long-term opioid drug consumption and subsequent abstinence in chronic noncancer pain patients receiving controlled-release morphine.
    Cowan DT, Wilson-Barnett J, Griffiths P, Vaughan DJ, Gondhia A, Allan LG.
    Pain Med; 2005 Apr 01; 6(2):113-21. PubMed ID: 15773875
    [Abstract] [Full Text] [Related]

  • 14. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ, Carr WD, Razzetti AJ, Sessler NE, Munera C, Ripa SR.
    Clin Ther; 2007 Oct 01; 29(10):2179-93. PubMed ID: 18042474
    [Abstract] [Full Text] [Related]

  • 15. A multicenter, randomized, double-blind, placebo-controlled trial of intravenous ibuprofen 400 and 800 mg every 6 hours in the management of postoperative pain.
    Southworth S, Peters J, Rock A, Pavliv L.
    Clin Ther; 2009 Sep 01; 31(9):1922-35. PubMed ID: 19843482
    [Abstract] [Full Text] [Related]

  • 16. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
    Simpson DM, Messina J, Xie F, Hale M.
    Clin Ther; 2007 Apr 01; 29(4):588-601. PubMed ID: 17617282
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of a new once daily hydromorphone formulation in comparison with twice daily administration in chronic pain: a randomized, double-blind, cross-over study.
    Nold GE, Maritz MA, Schwittay A, Schumann C, Rey H.
    Curr Med Res Opin; 2016 May 01; 32(5):869-77. PubMed ID: 26824884
    [Abstract] [Full Text] [Related]

  • 18. Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management.
    Lauretti GR, Perez MV, Reis MP, Pereira NL.
    J Clin Anesth; 2002 Mar 01; 14(2):83-6. PubMed ID: 11943517
    [Abstract] [Full Text] [Related]

  • 19. Randomised trial of oral morphine for chronic non-cancer pain.
    Moulin DE, Iezzi A, Amireh R, Sharpe WK, Boyd D, Merskey H.
    Lancet; 1996 Jan 20; 347(8995):143-7. PubMed ID: 8544547
    [Abstract] [Full Text] [Related]

  • 20. Gabapentin as add-on to morphine for severe neuropathic or mixed pain in children from age 3 months to 18 years - evaluation of the safety, pharmacokinetics, and efficacy of a new gabapentin liquid formulation: study protocol for a randomized controlled trial.
    de Leeuw TG, Mangiarini L, Lundin R, Kaguelidou F, van der Zanden T, Pasqua OD, Tibboel D, Ceci A, de Wildt SN, GAPP consortium.
    Trials; 2019 Jan 15; 20(1):49. PubMed ID: 30646965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.